Contact
Please use this form to send email to PR contact of this press release:
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythmâ„¢ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
TO: